27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- GlaxoSmithKline Plc (NYSE:GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co.
- The study will enroll 4,000 participants and compare the shot to Oxford University - AstraZeneca Plc (NASDAQ:AZN).
- The trial will test SK's protein-based vaccine candidate, GBP510, in combination with Glaxo, providing an adjuvant that can enhance the response to vaccines.
- Results from the Phase 3 study are expected in 1H of 2022, after which, subject to positive outcomes and regulatory approval, the vaccine is expected to be supplied at scale worldwide through the COVAX facility.
- Glaxo has been developing adjuvants for other vaccines developed by Sanofi SA (NASDAQ:SNY) and Medicago.
- Related Content: Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine
- Also Read: GSK Kick Starts Late-Stage Study With Medicago-Partnered COVID-19 Vaccine
- GSK is also working with CureVac BV (NASDAQ:CVAC) to jointly develop next-generation mRNA vaccines for COVID-19 to tackle multiple emerging variants in one vaccine.
- Related: GlaxoSmithKline, CureVac In Pact To Develop Vaccines For COVID-19 Variants
- Price Action: GSK shares are down 0.81% at $40.58 during the premarket session on the last check Tuesday.
- Photo by hakan german from Pixabay
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!